(Q39158096)

9 September 2017

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma (English)

1 reference

9 September 2017

S Maïga

1

1 reference

9 September 2017

P Gomez-Bougie

2

1 reference

9 September 2017

S Bonnaud

3

1 reference

9 September 2017

C Gratas

4

1 reference

9 September 2017

P Moreau

5

1 reference

9 September 2017

S Le Gouill

6

1 reference

9 September 2017

C Pellat-Deceunynck

7

1 reference

9 September 2017

M Amiot

8

1 reference

9 September 2017

language of work or name

English

0 references

publication date

30 April 2013

1 reference

British Journal of Cancer

9 September 2017

1 reference

9 September 2017

108

1 reference

9 September 2017

1801-1806

1 reference

9 September 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2013.186

9 September 2017

0 references

cites work

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Insulin and insulin-like growth factor signalling in neoplasia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Lenalidomide: a new therapy for multiple myeloma

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

A new mathematical model for relative quantification in real-time RT-PCR

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3658519

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

25 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.186

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23632478

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2013.186

1 reference

Dimensions Publication ID

9 September 2017

0 references

1 reference

9 September 2017

1 reference